Stephanie Hamilton

Stephanie brings over 25 years of experience in bioanalytical testing supporting infectious disease drug discovery and vaccine development across the pharmaceutical and biotechnology industries. Prior to joining 360biolabs, she held research and development roles focused on influenza vaccine development and served as technical lead on multiple pre-clinical programs and IND submissions targeting Hepatitis C, Influenza, Rhinovirus, and Respiratory Syncytial Virus.

At 360biolabs, Stephanie leads the Virology and Biomarker groups, overseeing the development and validation of live virus neutralisation assays, ELISpot, and plate-based immunoassays. These assays support clinical trials for vaccines targeting SARS-CoV-2, Chikungunya, Zika, Measles, Rubella, Herpes, Adenovirus, and Influenza, and  immunotherapy and oncology trials including CAR-T programs.

Stephanie holds a BSc (Hons) in Immunology from the University of Essex (UK) and a Master of Public Health from Monash University (Australia).